BMRA logo

BIOMERICA INC

BMRANASDAQ
🏆 #5093 by market capEarnings Oct 21US Equity
$2.30▼ $0.09 (−3.76%)
🌙 After hours$2.30▲ 0.00%Regular close · extended-hours price shown
🔔
Track BMRA
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 3.8%
7d▼ 15.8%
14d▼ 1.7%
30d▲ 7.7%
ytd▼ 8.0%
1y▼ 19.3%
🏦Market Cap
$7M
Small Cap
📈Revenue Growth (YoY)
-16.2%
Declining
📊Gross Margin
8.1%
Thin
💵FCF Margin
-77.7%
Thin
⚖️P/S Ratio
1.6x
Cheap
Otter Score
60
Fair

Trading Snapshot

Day Range
$2.28 – $2.32
52-Week Range
$1.45 – $3.21
Volume
$2.84B
Avg Volume
$3.17B
Shares Outstanding
3.1M
Next Earnings
Dec 11, 2026

Fundamentals Snapshot

Annual Revenue
$4M
Last Q Revenue
$875,000
P/E Ratio
-1.8
P/S Ratio
1.6x
EPS (TTM)
$-1.23
Dividend Yield
0.00%
Dilution (1yr)
+5.6%

Why Investors Own BMRA

  • ✓High-growth profile — revenue up +49.5% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 29% gross margin and 21% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BMRA logo

BIOMERICA INC

BMRA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$4M▼ −16.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
8.1%▼ −13.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$5M▲ +3.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$3M▼ −11.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
3.1M▲ +5.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$575K▼ −$3M YoY
StockOtter · stockotter.space

About BIOMERICA INC

Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Ratings

ⓘ
Consensus
Buy
7 analysts
Strong Buy3
Buy3
Hold1
Sell0
Strong Sell0
Ratings as of Jul 2022

Latest News & Updates

Defense World·19d ago

Head-To-Head Survey: Biomerica (NASDAQ:BMRA) versus Cytosorbents (NASDAQ:CTSO)

Cytosorbents (NASDAQ: CTSO - Get Free Report) and Biomerica (NASDAQ: BMRA - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the st

GlobeNewsWire·28d ago

Biomerica Reports Fiscal 2026 Year-End Financial Results

IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) today reported its financial results for the fiscal year ended May 31, 2026 (“Fiscal 2026”).

GlobeNewsWire·Aug 27

Biomerica Announces $2.23 Million Financing

IRVINE, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (“Biomerica” or the “Company”), a developer and manufacturer of diagnostic test systems, today announced that it has entered into definitiv